The clinical and biological features of acute myeloid leukemia (AML) with 11q23/MLL translocations are well known, but the characteristics of AML with partial tandem duplication of the MLL gene have not been explored comprehensively. In this study, MLL duplication was analyzed, in 81 AML patients without chromosomal abnormalities at 11q23, using Southern blotting, genomic DNA polymerase chain reaction (PCR), reversetranscription PCR and complementary DNA sequencing. Nine patients showed partial tandem duplication of the MLL gene, including eight (12%) of the 68 with normal karyotype. Seven patients showed fusion of exon 6/exon 2 (e6/e2), one, combination of differentially spliced transcripts e7/e2 and e6/e2, and the remaining one, combination of e8/e2 and e7/e2. Among the patients with normal karyotype, children aged 1 to 15 showed a trend to higher frequency of MLL duplication than other patients (2/5 or 40% vs 6/62 or 10%, P = 0.102). The patients with tandem duplication of the MLL gene had a significantly higher incidence of CD11b expression on leukemic cells than did those without in the subgroup of patients with normal karyotype (75% vs 28%, P = 0.017). There were no significant differences in the expression of lymphoid antigens or other myeloid antigens between the two groups of patients. In adults, the patients with MLL duplication had a shorter median survival time than those without (4.5 months vs 12 months, P = 0.036). In conclusion, partial tandem duplication of the MLL gene is associated with increased expression of CD11b on leukemic blasts and implicates poor prognosis in adult AML patients. The higher frequency of MLL duplication in children older than 1 year, than in other age groups, needs to be confirmed by further studies.
Introduction
The prognostic impact of chromosomal aberrations in acute leukemia has been well recognized and non-random cytogenetic abnormalities are increasingly applied to treatment planning and monitoring of the disease. 1 The chromosomal alterations at 11q23 are among the most common cytogenetic abnormalities in acute leukemia and may be involved in leukemogenesis. [2] [3] [4] Recently, the MLL (for mixed-lineage or myeloid-lymphoid leukemia) gene that spans the 11q23 breakpoints has been cloned; this encodes a protein with several regions of homology to the Drosophila trithorax protein and is a putative transcription factor. 5, 6 Rearrangements of the MLL gene can be demonstrated not only in most acute leukemias with various 11q23 translocations [7] [8] [9] but also in some acute myeloid leukemia (AML) without cytogenetic abnormalities at 11q23. [10] [11] [12] gene in the latter condition has revealed that the gene is rearranged by partial tandem duplication. 13 The duplication involves a portion of the gene corresponding to the aminoterminus of the MLL protein which contains the AT hook and a region of homology to DNA methyltransferase (MT) motifs, two domains suggested to be critical for leukemogenesis. 14 AMLs with 11q23/MLL translocation are well-characterized as occurring more frequently in infants than in adults and children older than 1 year, usually show M4/M5 phenotype, and coexpress myeloid-and lymphoid-associated antigens. 8, 15, 16 However, the clinical and biological characteristics of AML with partial tandem duplication of the MLL gene have not been studied comprehensively. These patients were found to have a poor prognosis, 17, 18 and almost all patients who achieved a complete remission relapsed; however, the treatments of choice for these patients are not clear. In addition, the age distribution and immunophenotype of the leukemic cells in this subgroup of AML patients are totally unknown. In this study, partial tandem duplication of the MLL gene was studied in 81 AML patients without 11q23 abnormalities; 68 of them had normal karyotype. It was found that children older than 1 year tend to have a higher incidence of partial tandem duplication of the MLL gene than infants and adults, and the patients with the gene change had a higher frequency of CD11b expression on the leukemic cells than others. The adult AML patients with the gene rearrangement had a shorter median survival time than those without the gene change. Two of the three patients with MLL duplication who received allogeneic stem cell transplantation remained in continuous complete remission (CR) at 27 and 41 months, respectively, suggesting that this procedure may reverse the poor outcome of this subgroup of patients.
Patients and methods

Patients
Partial tandem duplication of the MLL gene was studied in 81 newly diagnosed patients with de novo AML at presentation in the National Taiwan University Hospital. Patients with normal karyotype were selectively recruited, and those with chromosomal abnormalities involving 11q23 were excluded. No patients had a history of prior exposure to chemotherapy or radiotherapy, and none had a history of other underlying hematological or malignant disorders. The median age was 46 years, ranging from 4 months to 80 years. There were three infants, seven children (Ͼ1 years, р15 years), and 71 adults. Forty-two were males and 39, females. The diagnosis and classification of AML were based on the criteria established by the French-American-British (FAB) Cooperative Study Group. 19 
Cytogenetic study
Chromosome analysis was performed as described previously. 22 Briefly, bone marrow (BM) cells were harvested either directly or after 1-3 days of nonstimulated culture. Metaphase chromosomes were banded by the conventional trypsin-Giemsa banding technique and karyotyped according to the International System for Human Cytogenetic Nomenclature. 23 
Immunophenotyping
A panel of monoclonal antibodies (Immunotech, Marseille, France) to myeloid-associated antigens including CD13, CD33, CD11b, CD14, CD15, glycophorin A and CD41a, as well as to lymphoid-associated antigens including CD2, CD5, CD7, CD10, CD19 and CD20, and to lineage-nonspecific antigens CD34 and HLA-DR, were selected to characterize immunological phenotypes of leukemic cells. An indirect immunoalkaline phosphatase method was applied to detect the expression of surface antigens on leukemic cells. 24 The cut-off value for positive result of the markers was more than 20%.
Nucleic acid preparation
Mononuclear cells obtained from bone marrow aspirates were isolated by Ficoll-Hypaque gradient centrifugation and cryopreserved on the same day of sample collection with a few exceptions. Genomic DNAs were extracted by using a conventional isolation method. 24 Total cellular RNAs were extracted from cryopreserved cells by a modified one-step guanidinium thiocyanate-phenol-chloroform method using RNAzol B commercial reagent (Biotecx Laboratories, Houston, TX, USA) as described previously. 25 
Detection of partial tandem duplication of the MLL gene
Partial tandem duplication of the MLL gene was detected by Southern blot analysis, genomic DNA polymerase chain reaction (PCR), reverse-transcription PCR (RT-PCR) and complementary DNA (cDNA) sequencing.
Southern blot analysis was performed as described previously. 12 Genomic DNAs were digested with restriction enzymes BamHI and HindIII. After being size-fractionated by electrophoresis and transferred to Hybond membrane Leukemia (Amersham Pharmacia Biotech, Amersham, UK), they were hybridized with 32 P-dCTP-labelled probe. The probe used was a 740-bp cDNA fragment of the MLL gene spanning exons 5 to 11 (kindly provided by JR Downing, St Jude Children's Research Hospital, Memphis, TN, USA).
PCR of the genomic DNAs was done according to the method described previously. 22 The primer set used was the same as that designed by Caligiuri et al: 26 6.1 (5Ј-GTCCA-GAGCAGAGCAAACAG-3Ј) from exon 6 (sense orientation) and 2.0R (5Ј-CGCACTCTGACTTCTTCATC-3Ј) from exon 2 (antisense orientation).
Reverse transcription was performed at 37°C for 1.5 h in a volume of 20 l including 1 to 5 g of total cellular RNA, 50 ng of random hexamer, 25 units rRNasin, 200 units M-MLV reverse transcriptase (Promega, Madison, WI, USA), deoxynucleotides (final concentration 0.5 mM each), and 4 l of 5× RT buffer as described previously. 25 The cDNA was then amplified by nested PCR. 25 The PCR primer set for the first round amplification was 5.3 (5Ј-GGAAGTCAAGCAAGCAG GTC-3Ј) from exon 5 (sense) and 654c (5Ј-AGGAGAGAGTTT ACCTGCTC-3Ј) from exon 3 (antisense), as reported by Caligiuri et al, 26 and that for the second round amplification was 6.1 from exon 6 (sense) and 400c (5Ј-ACACAGATGGATCTG AGAGG-3Ј) from exon 3 (antisense). PCR was run in a volume of 50 l containing 5 l of 10× PCR buffer, 2.5 l of each primer (final concentration 0.5 M each), deoxynucleotides (final concentration 125 M each) and 1 unit Taq DNA polymerase (Qiagen, Valencia, CA, USA). The mixture was denatured at 95°C for 1 min, annealed at 60°C for 1 min and extended at 72°C for 1 min for 35 cycles. All the PCR products were analyzed by electrophoresis on 2.0% agarose gel and visualized with ethidium bromide under an ultraviolet lamp.
The presence of partial tandem duplication of the MLL gene was also confirmed by direct cDNA sequencing using a method described previously. 25 The PCR-amplified cDNA was gel purified, and then sequenced using the Applied Biosystems 373A DNA sequencer (Perkin-Elmer Corporation, Foster City, CA, USA) with data-processing programs from the Genetics Computer Group system (IntelliGenetics, Campbell, CA, USA).
Statistics
Continuous variables were compared by Wilcoxon rank-sum test and discrete ones, by 2 or Fisher's exact test. Curves of survival and complete remission duration were plotted by the Kaplan-Meier method; differences between curves were analyzed by the log-rank test. The patients who received allogeneic hematopoietic stem cell transplantation were censored at the date of the procedure. The significance of results were defined as a level of P Ͻ 0.05 at both tails. All statistical analyses were done using the SPSS for Windows Release 10.0 (SPSS, Chicago, IL, USA).
Results
Partial tandem duplication of the MLL gene and its correlation with clinical and hematological features
Nine (11%) of the 81 patients were found to have partial tandem duplication of the MLL gene (Table 1 and Figures 1-3) . Seven patients showed fusion of MLL exon 6/exon 2 (e6/e2), one revealed combination of differentially spliced transcripts
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Figure 1
A representative film of genomic DNA PCR of the MLL gene showing amplified bands in lanes 1 to 6 (corresponding to cases 1, 9, 7, 2, 6 and 8, respectively). Case 8 (lane 6) had duplication spanning exons 2-8, and others had duplication spanning exons 2-6. M, marker; N, normal control. e7/e2 and e6/e2 (case 3), and the remaining one, combination of e8/e2 and e7/e2 (case 8). One patient who resulted positive in RT-PCR but negative in Southern blotting and genomic DNA PCR was not considered to have partial tandem duplication of the MLL gene and was excluded from the study.
The clinical and hematological features of the patients with the partially duplicated MLL gene were compared with those of the patients without the change (Table 2) . Among the 81 patients, 68 showed normal karyotype of the BM cells, 12 had chromosomal abnormalities, including two t(8;21), two t(7;11), one 3q abnormality and seven nonspecific aberrations. One patient did not have a cytogenetic study. Eight (12%) of the 68 patients with normal karyotype were found to have partial tandem duplication of the MLL gene. Cytogenetic data were not available for the one remaining case with partially duplicated MLL gene.
The median age was 34 years (range 13-79 years) in the group of patients with partial tandem duplication of the MLL gene, compared with 47 years (range 0.3-80 years) in the group without the change (P = 0.266). Partial tandem duplication of the MLL gene was found in two (29%) of the seven children aged between 1 and 15 years, compared with that in eight (11%) of the 71 adults and none of the three infants; however, the difference did not reach statistical significance (P = 0.266). The trend became more prominent when the analysis was performed only on the patients with normal karyotype (2/5 or 40% in children older than 1 year, vs 6/62 or 10% in adults, and 0/1 in infants, P = 0.102). There was a trend to a lower hemoglobin (Hb) level in the group of patients with MLL duplication than in others (Hb 6.4 g/dl vs 8.5 g/dl, P = 0.056). Other clinical and hematological features were not significantly different between the two groups of patients. Similar results could be demonstrated when the analyses were carried out separately on the adults and children (Table 2) or on the subgroup of patients with normal karyotype (data not shown).
Correlation of partial tandem duplication of MLL gene with FAB subtype and immunophenotype
Among the 81 newly diagnosed AML, 24 were M1, 32 M2, 19 M4, four M5, one M7 subtypes, and one undetermined. Three of the M4 patients (16%), four of the M2 patients (13%), two of the M1 patients (8%) and none of the M5 and M7 patients showed partial tandem duplication of the MLL gene; the difference was not statistically significant (P = 0.865). The patients with partial tandem duplication of the MLL gene revealed a trend to higher frequency of CD11b expression than those without the gene rearrangement (67% vs 28%, P = 0.051, Table 3 ); the difference became statistically significant when the analysis was restricted to the patients with normal karyotype (75% vs 28%, P = 0.017). There were few differences in the expression of other surface antigens between the two groups of patients whether the analyses were performed The data in this table were from the analysis on all patients studied.
When only the patients with normal karyotype were included in the analysis, six (75%) of eight patients with MLL duplication and 11 (28%) of the 40 patients without the change showed CD11b expression on leukemic cells; the difference was statistically significant (P = 0.017). However, there were still no differences in the expression of other surface antigens between the patients with and without MLL duplication. b The results of CD41a, CD5, CD10, CD19 and CD20 are not shown. There was no difference in the expression of these markers between the two groups of patients.
Leukemia on all patients who had undergone the study or only on those with normal karyotype (Table 3) .
Correlation of partial tandem duplication of the MLL gene with outcome
Sixty-two patients, including seven with partially duplicated MLL gene and 55 without, underwent conventional combination chemotherapy, which consisted of cytarabine and one of the anthracyclines; these patients were the subjects of the outcome analysis. The CR rate was not significantly different between the patients with partial tandem duplication of the MLL gene and those without (57% with 95% confidence interval, CI: 8-107% vs 69% with 95% CI: 56-82%, P = 0.671, Table 2 ). Three of the four patients who had partial tandem duplication of the MLL gene and achieved CR received allogeneic hematopoietic stem cell transplantation; two of them, one child and one adult, remained in continuous CR at 41 and 27 months, respectively, and the third one, a child, relapsed 8 months after the procedure, but was still alive with a survival time of 25 months at the date of analysis. The one remaining patient was treated with conventional consolidation chemotherapy and died from complications during the treatment. Among the 38 patients without the MLL duplication who achieved CR, five received allogeneic hematopoietic stem cell transplantation; three of them were in continuous CR at 96, 36 and 21 months, respectively, one relapsed, and the remaining one died of chronic hepatitis B with acute exacerbation while in CR. Among the remaining 33 patients, apart from the one who received no further treatment after obtaining CR, 32 patients were treated with either standard-dose consolidation chemotherapy (21 patients) or high-dose cytarabine with or without anthracyclines or VP-16 (11 patients). Six of the 33 patients were alive and remained in first CR, three died from complications during consolidation chemotherapy, two were lost to follow-up while in first CR, and 22 relapsed. The median CR duration and survival time between the two groups of patients with partial tandem duplication of the MLL gene and those without were not different (not reached vs 10 months, P = 0.561 and 4.5 months vs 12 months, P = 0.141, respectively, Table 2) . Similar results could be demonstrated when the analyses were performed only in the patients with normal karyotype (median CR duration: not reached vs 10 months, P = 0.490 and median survival time 4.5 months vs 12 months, P = 0.164). However, when the analysis was performed only in the adults, the patients with partial tandem duplication of the MLL gene had a significantly shorter median survival time than those without (4.5 months vs 12 months, P = 0.036, Table 2 and Figure 4 ), but the CR rate and CR duration were not statistically different between the two groups of patients.
Discussion
In this study, partial tandem duplication of the MLL gene was found in 11% of all AML patients and 12% of those with normal karyotype, incidences similar to those reported in the literature. 17, 18, 27 Although infant AML was found to have a high frequency (around 50%) of the MLL gene rearrangement, they usually involved reciprocal translocation of the MLL gene with its partner genes. 8, 12, 16, 28 Little is known about the frequency of partial tandem duplication of the MLL gene in infant as well as in other pediatric AML. In this study, we did not observe such abnormality in any infant, but children older than 1 year tended to have a higher frequency of MLL duplication than patients in other age groups, especially among the patients with normal karyotype. Because the number of cases studied is limited, these results need to be confirmed by further studies in more pediatric patients. All other studies regarding the MLL gene duplication were performed on adults 17, 18, 27 with one exception, in which a slightly higher incidence of MLL duplication in pediatric AML than in adult AML was suggested. 29 The only child, aged 9, recruited in the study of Schnittger et al, 18 also showed tandem duplication of the MLL gene. Similar to other reports, we did not observe a significantly higher incidence of the MLL duplication in the FAB M4/M5 subtypes than others, in contrast to the finding that translocation of the 11q23/MLL gene occurred more frequently in monocytic leukemia than in other AML subtypes. 16 This is the first report to demonstrate a significantly higher frequency of CD11b expression on leukemic blasts in AML patients with partial tandem duplication of the MLL gene than in those without the abnormality in the subgroup of patients with normal karyotype (75% vs 28%, P = 0.017). Expression of other markers including monocyte-associated antigen CD14 and lymphoid-associated antigens showed little difference between the two groups of patients. Animal studies have shown that the MLL gene is required for differentiation of hematopoietic cells, especially along the myeloid and macrophage pathways, which is accompanied by expression of the myeloid-associated antigens CD11b and CD14. 30, 31 On the other hand, the human leukemic cell line expressing AT hook domain of the amino-terminus of the MLL gene alone, the region involved in tandem duplication, expressed CD11b, but not CD14. 32 This finding might explain the difference in the incidence of CD11b expression, but not CD14 expression, between the patients with partial tandem duplication of the MLL gene and those without. To our knowledge, no other study regarding surface marker expression in AML with the MLL gene duplication has been reported.
The portion most frequently involved in MLL duplication in this study was exons 2 to 6, similar to that reported by others. 17, 18, 27 Duplication of exons 2 to 7 or exons 2 to 8, with or without alternative splicing, was also commonly seen. 17, 18, 27 Exon 3 and exons 4 to 6, involved in almost all cases with partial tandem duplication of the MLL gene, encode AT hook and MT motifs of the MLL gene protein, respectively, and duplication of these critical regions may play important roles in leukemogenesis. 14, 33, 34 Partial tandem duplication of the MLL gene has been detected in peripheral blood and bone marrow cells of healthy donors by nested RT-PCR. 35 However, in contrast to leukemic cells with partial tandem duplication of the MLL gene, in normal cells with fusion transcript, a corresponding genomic rearrangement of the MLL gene could not be demonstrated by Southern blotting or genomic DNA PCR. 36 It has been suggested that the MLL fusion transcript detected in normal cells results from differential mRNA splicing rather than true genomic rearrangement. 36 All nine patients with MLL duplication in this study showed genomic rearrangement of the gene.
In the limited number of reports, AML patients with partial tandem duplication of the MLL gene were shown to have shorter CR duration and/or overall survival time, compared with those without the abnormality. 17, 18, 37 Almost all patients with MLL duplication who achieved a CR relapsed. 17, 18 The only patient remaining in continuous CR reported by Caligiuri et al 17 received eight intensive cycles of combination chemotherapy. In another report, eight of 10 AML patients with MLL duplication who obtain a CR relapsed, one died with aplasia of the bone marrow, and the remaining one died from complications of allogeneic bone marrow transplantation. 18 In this study, three of the four patients with partial tandem duplication of the MLL gene who gained CR received allogeneic hematopoietic stem cell transplantation, and two of them remained in continuous CR at 27 and 41 months, respectively. Although the data are limited, it is suggested that hematopoietic stem cell transplantation or very intensive consolidation chemotherapy may be indicated to reverse the poor prognosis of AML patients with tandem duplication of the MLL gene. In one study, 38 in which 17 of the 41 recruited AML patients with normal karyotype received autologous or allogeneic hematopoietic stem cell transplantation, the patients with MLL self-fusion showed similar outcome to those without the gene change. Prospective studies in more patients are needed to discover the best treatment for patients with tandem duplication of the MLL gene.
In conclusion, partial tandem duplication of the MLL gene occurs in a substantial number of AML patients without cytogenetic aberrations at 11q23, especially in those with normal karyotype. MLL self-fusion is associated with the expression of certain surface antigens on myeloid leukemic blasts. Whether the frequency of MLL duplication in children older than 1 year is higher than other age groups needs to be confirmed by further studies in more patients. In adult AML patients, MLL duplication implies poor prognosis. The necessity of allogeneic hematopoietic stem cell transplantation in this subgroup of AML patients remains to be elucidated.
